Guillaume D.
- Country
- France
- Department
- Rhumatologie
Research Overview
- Comparison of Bimekizumab versus Adalimumab for the Treatment of Anterior Chest Wall Pain in Patients with Active Axial Spondyloarthritis Refractory to NSAIDs
- Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. A randomized controlled trial with an independent efficacy assessor.
- Open-Label Extension Study Evaluating Long-Term Safety and Tolerability of Subcutaneous Secukinumab in Patients with Polymyalgia Rheumatica
Data & Insights
Has run more than one trial at 102 of 196 partner sites.
Specializations
Rheumatic Disorders
This investigator specializes in the treatment of rheumatoid arthritis, conducting research on innovative therapeutic approaches including JAK inhibitors and combination therapies with anti-TNF agents.
- Treatment optimization strategies
- Dose tapering protocols
- Combination therapy approaches
Their work focuses on managing disease activity and improving treatment outcomes for patients with refractory conditions.
Inflammatory Conditions
The investigator has extensive experience in treating giant cell arteritis and polymyalgia rheumatica, exploring various therapeutic interventions including tocilizumab and secukinumab.
- Long-term safety assessments
- Comparative treatment efficacy
- Glucocorticoid management
Their research encompasses both immediate and gradual treatment discontinuation protocols in inflammatory conditions.
Musculoskeletal Disorders
The investigator conducts research in rotator cuff tendinopathy and postmenopausal osteoporosis, investigating novel therapeutic approaches and treatment strategies.
- Shoulder symptom management
- Bone density interventions
- Treatment withdrawal strategies
Their work includes evaluating biomarker-driven treatments and physical symptom improvement in musculoskeletal conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.